For example, the recommendations for the use of the new anti-diabetes therapy of glucagon like peptide-1 receptor agonists (GLP-1RA) and sodium glucose transporter-2 (SGLT-2) inhibitors are to be only carefully considered in frail individuals due to the risk of weight loss, dehydration and hypotension [4, 5]. The gene discussed is SLC5A2; the disease is diabetes mellitus.